Education
2016 - 2020
2016 - 2020Doctorate
University of Newcastle Upon Tyne, Faculty of Medical Sciences, Centre for Cancer, England
2012 - 2014
2012 - 2014Postgraduate
Istanbul University, Health Sciences Institute, Genetik (Yl) (Tezli), Turkey
2007 - 2012
2007 - 2012Undergraduate
Ege University, Faculty of Engineering, Bioengineering, Turkey
Dissertations
2020
2020Doctorate
The MDM2-p53 signalling network and sf3b1 status in chronic lymphocytic leukaemia
University of Newcastle Upon Tyne
2014
2014Postgraduate
JAK2V617F mutasyonunun altın nanoflares kullanılarak tespiti
Istanbul University, Sağlık Bilimleri Enstitüsü, Genetik (Yl) (Tezli)
Foreign Languages
C1 Advanced
C1 AdvancedEnglish
Research Areas
Medical Genetics
Molecular Biology and Genetics
Moleculer Biology of Cancer
Cytogenetic
Research Areas Based on Academic Activities
Avesis Research Areas
WoS Research Areas
Scopus Research Areas
Academic Positions
2026 - Present
2026 - PresentAssociate Professor
Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik
2023 - 2026
2023 - 2026Assistant Professor
Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik
2020 - 2023
2020 - 2023Lecturer PhD
Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik
Managerial Experience
2026 - Present
2026 - PresentProject Development & Coordination Office Coordinator
Bilecik Seyh Edebali University, Rektörlük
2025 - Present
2025 - PresentMember Of Scientific Research Projects Committee
Bilecik Seyh Edebali University, Rektörlük
2022 - Present
2022 - PresentErasmus Program Department Coordinator
Bilecik Seyh Edebali University, Fen Fakültesi, Moleküler Biyoloji Ve Genetik
2020 - Present
2020 - PresentDeputy Director of the Center
Bilecik Seyh Edebali University, Biotechnology Application and Research Center
Articles
All (13)
SCI-E, SSCI, AHCI (11)
SCI-E, SSCI, AHCI, ESCI (11)
Scopus (11)
TRDizin (2)
2025
20251. Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia.
Aptullahoglu E., Kaygusuz E.
International journal of molecular sciences
, vol.26, no.17, 2025 (SCI-Expanded, Scopus)
2025
20252. Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme
APTULLAHOĞLU E.
Osmaniye Korkut Ata Üniversitesi Fen Bilimleri Enstitüsü Dergisi (Online) , vol.8, no.4, 2025 (TRDizin)
2025
20253. Preclinical Evaluation of Brigimadlin (BI 907828) As a Novel MDM2 Inhibitor in Acute Lymphoblastic Leukemia
APTULLAHOĞLU E.
Black Sea Journal of Engineering and Science , vol.8, no.5, pp.1450-1459, 2025 (TRDizin)
2025
20254. Brigimadlin (BI-907828) and napabucasin (BBI608) cooperatively trigger apoptosis in chronic lymphocytic leukemia cells by simultaneous iİnhibition of MDM2 and STAT3.
APTULLAHOĞLU E.
Molecular biology reports
, vol.52, no.1, pp.731, 2025 (SCI-Expanded, Scopus)
2025
20255. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.
Aptullahoglu E., Howladar M., Wallis J. P., Marr H., Marshall S., Irving J., et al.
Cancers
, vol.17, no.2, 2025 (SCI-Expanded, Scopus)
2024
20246. Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.
Gungordu S., Aptullahoglu E.
Investigational new drugs
, vol.42, no.6, pp.603-611, 2024 (SCI-Expanded, Scopus)
2024
20247. RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia.
APTULLAHOĞLU E., Nakjang S., Wallis J. P., Marr H., Marshall S., Willmore E., et al.
Biomedicines
, vol.12, no.7, 2024 (SCI-Expanded, Scopus)
2023
20238. SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.
Aptullahoglu E., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., et al.
International journal of molecular sciences
, vol.24, no.14, 2023 (SCI-Expanded, Scopus)
2023
20239. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Aptullahoglu E., Ciardullo C., Wallis J. P., Marr H., Marshall S., Bown N., et al.
International journal of molecular sciences
, vol.24, no.3, 2023 (SCI-Expanded, Scopus)
2022
202210. p53 as a biomarker and potential target in gastrointestinal stromal tumors.
Wu C., Chen C., Huang W., Pan Y., APTULLAHOĞLU E., Yeh C., et al.
Frontiers in oncology
, vol.12, pp.872202, 2022 (SCI-Expanded, Scopus)
2019
201911. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C., Aptullahoglu E., Woodhouse L., Lin W., Wallis J. P., Marr H., et al.
Haematologica
, vol.104, no.12, pp.2429-2442, 2019 (SCI-Expanded, Scopus)
2019
201912. In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology.
Sozer S., Aptullahoglu E., Shivarov V., Yavuz A. S.
International journal of laboratory hematology
, vol.41, no.4, 2019 (SCI-Expanded, Scopus)
2018
201813. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu C., Esfandiari A., Ho Y., Wang N., Mahdi A. K., Aptullahoglu E., et al.
British journal of cancer
, vol.118, no.4, pp.495-508, 2018 (SCI-Expanded, Scopus)
Papers Presented at Peer-Reviewed Scientific Conferences
2025
20251. Kronik Lenfositik Lösemide Sinerjistik İlaç Etkileşimlerinin Nicel Değerlendirilmesine Yönelik ZIP Sinerji Skorlama ve Chou-Talalay Modellerinin Yöntemsel Karşılaştırması
APTULLAHOĞLU E.
26. ULUSAL BİYOLOJİ KONGRESİ (UBİKON 2025), 03 September 2025, (Summary Text)
2025
20252. Identification Of Key Predictive Biomarkers For mTOR Inhibitor Response In Leukemia Cell Lines Using Multi-Omics Database Mining And Statistical Modeling
APTULLAHOĞLU E.
6th International Congress of Applied Statistics (UYİK 2025), 14 May 2025, (Summary Text)
2019
20193. Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells
Willmore E., APTULLAHOĞLU E., Zhao Y., Kyle S., Thomas H., Ahn M., et al.
The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 September 2019, (Summary Text)
2019
20194. The spliceosome inhibitor E7107 induces a dose-dependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes
APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.
The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 September 2019, (Summary Text)
2018
20185. E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes
APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.
The 25th Biennial Congress of the European Association for Cancer Research (EACR25), Amsterdam, Netherlands, 30 June - 03 July 2018, (Summary Text)
2017
20176. Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells
Wu C., Esfandiari A., Ho Y., Shepherd C., Mahdi A. K., APTULLAHOĞLU E., et al.
(AACR) 2017 Annual Meeting, Washington, Kiribati, 1 - 05 April 2017, (Summary Text)
2016
20167. The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia
Ciardullo C., Woodhouse L., APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., et al.
58th ASH Annual Meeting Exposition, San Diego, 3 - 06 December 2016, vol.128, pp.893, (Summary Text)
2014
20148. In-Cell Detection By Flow Cytometry of JAK2 V617F Mutation Using Gold Nanoflares
APTULLAHOĞLU E., Uslu I., Yavuz A. S., Shivarov V., Sozer S.
56th ASH Annual Meeting Exposition, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, pp.4586, (Summary Text)
Books
2022
20221. Technical English for Bioengineering Students
APTULLAHOĞLU E.
Cinius Yayınları, İstanbul, 2022
2021
20212. Professional English for Molecular Biology Students
APTULLAHOĞLU E.
Cinius Yayınları, 2021
2020
20203. Mutasyon Tespitinde Altın Nanopartikül Ajanı Kullanımı
APTULLAHOĞLU E.
CİNİUS YAYINLARI, İstanbul, 2020
Funded Projects
2025 - 2025
2025 - 2025From Nature to Biotechnology Laboratory: Experiencing Modern Biotechnology Techniques with Teachers and Shaping the Future
TUBITAK Project , 4004 - Nature Education and Science Schools
Aptullahoğlu E., İzgördü H., Akpınar Borazan A.
2024 - 2025
2024 - 2025Investigating Pharmacological Inhibition of mTORC2 with JR-AB2-011 in Acute Lymphoblastic Leukemia Using Preclinical Methods
TUBITAK Project , 1002 - Quick Support Program
(Project Abstract)
Aptullahoğlu E. (Executive), Akpınar Borazan A., Gurbanov R., İzgördü H.
2021 - 2024
2021 - 2024Investigating the Combined Targeting of MDM2 and STAT3 as a New Therapeutic Approach in Acute Lymphoblastic Leukemia
TUBITAK Project , 3501 - National Young Researcher Career Development Program
Aptullahoğlu E. (Executive), Kaygusuz E.
2015 - 2017
2015 - 2017Biomarker assessment and therapeutic targeting of the MDM2-p53 signalling network in chronic lymphocytic leukaemia (CLL) - University of Newcastle Upon Tyne
Civil Society Organizations of Other Countries Supported Project
Lunec J.(Executive), Aptullahoğlu E.
2013 - 2014
2013 - 2014JAK2V617F Mutasyonunun Endotel Hücre Fonksiyonları Üzerindeki Rolü (Bursiyer araştırmacı)
TUBITAK Project , 1001 - Program for Supporting Scientific and Technological Research Projects
Awards
January 2014
January 2014Overseas PhD Scholarship (Granted to three individuals in the field of Molecular Biology within the country)
Milli Eğitim Bakanlığı
January 2014
January 2014ASH (American Society of Hematology) Annual Meeting - Abstract Achievement Award
The Wallace H. Coulter Foundation